CCM
AQST icon

Corsair Capital Management’s Aquestive Therapeutics AQST Stock Holding History

Corsair Capital Management’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$291K Buy
70,000
+10,000
+17% +$40.6K 0.04% 130
2025
Q4 		$388K Buy
+60,000
New +$374K 0.06% 112

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Corsair Capital Management's AQST Position: Q1 2026 in Review

Corsair Capital Management increased its Aquestive Therapeutics (AQST) stake by 17% in Q1 2026, buying an estimated $40.6K and bringing the position to 70,000 shares worth $291K. The position accounts for 0.04% of the portfolio, ranked #130.

Corsair Capital Management first reported a position in AQST in Q4 2025 and has held it in 2 quarters since. The position peaked at $388K in Q4 2025. 179 funds tracked by Wall St. Rank hold AQST as of Q1 2026.

  • Corsair Capital Management held 70,000 shares of Aquestive Therapeutics worth $291K as of Q1 2026.
  • Corsair Capital Management bought 10,000 Aquestive Therapeutics shares in Q1 2026, an estimated $40.6K.
  • Aquestive Therapeutics made up 0.04% of Corsair Capital Management's portfolio in Q1 2026, its #130 holding.
  • Corsair Capital Management first reported a position in Aquestive Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Corsair Capital Management's Aquestive Therapeutics position peaked at $388K in Q4 2025.
  • 179 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q1 2026.

Based on Corsair Capital Management's 13F filing for Q1 2026, filed 15 May 2026.